Divi's Labs Q1 FY27 Consolidated Income at ₹3,144 Cr, PAT ₹902 Cr
Divi's Laboratories reported Q1 FY27 consolidated total income of ₹3,144 crore, up from ₹2,529 crore in Q1 FY26. Consolidated PAT increased to ₹902 crore from ₹545 crore year-on-year. Standalone PAT was ₹891 crore. The company appointed Mr. B. Vara Prasad and Mr. J. Srinivasa Rao as Senior Management Personnel, effective August 1, 2026.
The strong financial results and the appointment of key senior management personnel are material events that are likely to have a significant impact on the company's stock performance and investor sentiment.
The company reported significant year-on-year growth in consolidated total income and profit after tax, indicating strong financial performance.
Divi's Laboratories Limited announced its financial results for the quarter ended June 30, 2026, following a Board Meeting held on August 01, 2026. The company reported a consolidated total income of ₹3,144 crore, a significant increase from ₹2,529 crore in the corresponding quarter of the previous year.
Consolidated Profit Before Tax (PBT) stood at ₹1,180 crore, up from ₹733 crore in the prior year's quarter. Consolidated Profit After Tax (PAT) was ₹902 crore, compared to ₹545 crore in the same period last year. The company also reported a consolidated forex loss of ₹7 crore for the quarter.
On a standalone basis, Divi's Laboratories recorded a total income of ₹3,037 crore and a Profit After Tax (PAT) of ₹891 crore for the quarter ended June 30, 2026. The standalone forex gain/loss for the period was a loss of ₹7 crore.
The Board of Directors also approved the appointment of Mr. B. Vara Prasad and Mr. J. Srinivasa Rao as Senior Management Personnel, both with effect from August 01, 2026. Mr. Prasad, General Manager (Engineering Purchase), brings over 31 years of experience in supply chain and procurement. Mr. Rao, General Manager (Raw Materials Purchase), has over 30 years of experience in managing pharmaceutical procurement operations.
The Board Meeting commenced at 10:15 AM and concluded at 11:20 AM on August 01, 2026.
What to do with a filing like this
Divi's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Divi's Laboratories Limited. Read the original for the full detail.